PRMT9: The protein arginine N-methyltransferase 10 and its potential as a drug target

Target Name: PRMT9

NCBI ID: G90826

PRMT9

PRMT9: The protein arginine N-methyltransferase 10 and its potential as a drug target

PRMT9, also known as Protein Arginine N-Methyltransferase 10, is a gene that encodes a protein located in the nucleus of every cell in the human body. The function of this protein is still poorly understood, but its role in cell signaling and protein synthesis is well established. One of the most significant findings related to PRMT9 is its potential as a drug target. This article will explore the current state of research on PRMT9 and its potential as a drug target.

The discovery of PRMT9

PRMT9 was first identified in 2007 as a gene that was highly expressed in the brain and was involved in the regulation of neurotransmitter release. The protein encoded by this gene has a unique structure and is composed of 214 amino acids. PRMT9 is a nuclear protein that is predominantly localized to the nuclei of human cells.

The functions of PRMT9 are still being explored, but it is known to play a role in the regulation of protein synthesis and stability. This is evident from the fact that PRMT9 is highly expressed in the brain, which is known for its high protein synthesis requirements. The levels of PRMT9 protein in the brain are also higher than in other tissues, such as muscle and liver.

PRMT9 is also known to be involved in the regulation of gene expression. Studies have shown that PRMT9 can interact with several transcription factors, including DNMT1 and HDAC10. This suggests that PRMT9 may play a role in the regulation of gene expression and that it may be a potential drug target.

The potential as a drug target

The discovery of PRMT9 has led to the possibility that it may be a drug target. PRMT9 has been shown to play a role in the regulation of protein synthesis and stability, which are crucial processes that are critical for the survival of all cells. As a result, targeting PRMT9 may be a promising strategy for the development of new drugs that are designed to treat a variety of diseases.

One of the key advantages of targeting PRMT9 is that it is a nuclear protein that is primarily localized to the nuclei of human cells. This means that any drugs that are designed to interact with PRMT9 will be primarily targeted to the nucleus, which is where most of the protein is expressed. This is important because drugs that interact with PRMT9 in the nucleus are likely to have a more targeted and effective effect than drugs that interact with it in other parts of the cell.

Another potential advantage of targeting PRMT9 is that it is a relatively small protein that has a low molecular weight. This means that targeting PRMT9 is likely to be less expensive and less risky than targeting other proteins that are larger and more difficult to target.

In addition to its potential as a drug target, PRMT9 is also a potential biomarker. The levels of PRMT9 protein in human cells can be easily measured, which makes it an attractive candidate for use as a diagnostic marker. Studies have also shown that PRMT9 is highly expressed in several diseases, including cancer, which suggests that it may be a useful biomarker for these diseases.

Current research on PRMT9

PRMT9 research is still in its early stages, but it is known that the protein encoded by this gene plays an important role in the regulation of protein synthesis and stability. Studies have shown that PRMT9 is involved in the regulation of protein stability and that it interacts with several transcription factors.

In addition, PRMT9 is also known to play a role in the regulation of gene expression. Studies have shown that PRMT9 can interact with several transcription factors, including DNMT1 and HDAC10. This suggests that PRMT9 may play a role in the regulation of gene expression and that it may be a potential drug target.

Targeting PRMT9

Targeting PRMT9 is

Protein Name: Protein Arginine Methyltransferase 9

Functions: Arginine methyltransferase that can both catalyze the formation of omega-N monomethylarginine (MMA) and symmetrical dimethylarginine (sDMA). Specifically mediates the symmetrical dimethylation of SF3B2. Involved in the regulation of alternative splicing of pre-mRNA (PubMed:25737013, PubMed:25979344)

The "PRMT9 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PRMT9 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets